Get the Stockscreener App
88.41
0.10%
-0.09
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $88.41, with a volume of 41.63M.
It is down -0.10% in the last 24 hours and up +0.57% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$88.50
Open:
$88.64
24h Volume:
41.63M
Relative Volume:
3.09
Market Cap:
$153.99B
Revenue:
$45.13B
Net Income/Loss:
$6.28B
P/E Ratio:
24.63
EPS:
3.5895
Net Cash Flow:
$7.38B
1W Performance:
-1.38%
1M Performance:
+0.57%
6M Performance:
-29.34%
1Y Performance:
-33.23%
1-Day Range:
$87.76
$89.44
1-Week Range:
$87.07
$91.58
52-Week Range:
$81.97
$139.06
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Whistleblower Alleges Medical Giant Bribed Hawaiʻi Provider - Honolulu Civil Beat
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Citi Believes Abbott (ABT) Shares are Undervalued Relative to Business Segments - Insider Monkey
Abbott Laboratories Raised Prices, Prompting Sales Slump - WSJ
Ultrahuman M2 Live: Glucose Tracking Without a Prescription Using Abbott's Lingo Launches in the U.S. - Basic Tutorials
Why Abbott’s Libre Sense glucose sport biosensor keeps endurance athletes wired in - AD HOC NEWS
Abbott Laboratories director John Stratton buys $173,640 in shares - Investing.com
Director at Abbott (NYSE: ABT) buys 2,000 shares in open market - Stock Titan
Abbott Laboratories StockChart focus as shares test support - AD HOC NEWS
Ultrahuman Launches M2 Live in U.S. With Abbott Lingo™ CGM Integration - Digital Health News
Ultrahuman launches M2 Live with Abbott's Lingo glucose sensor - t2ONLINE
Abbott Laboratories stock underperforms Wednesday when compared to competitors - MarketWatch
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation - Yahoo Finance
Abbott Laboratories Stock Capital Return Hits $28 Bil - Trefis
Julie Johnson from Texas’s 32nd District Sells Shares in Abbott Laboratories and Accenture - Investing.com
Big Claims, Little Kids: Recent SDNY Decision Highlights Risks in Advertising (via Passle) - Frankfurt Kurnit Klein & Selz
Hormuz Reopening Trade: 20 Large-Caps Still Below Pre-War LevelsAbbott Laboratories (NYSE:ABT), PepsiC - Benzinga
Texas Rep. Julie Johnson Sold Up to $30K Worth of Abbott Laboratories Stock - Benzinga
How Investors May Respond To Abbott (ABT) Dividend And CE Mark For Dual Glucose‑Ketone Sensor - Yahoo Finance
Can S&P 500 Healthcare Giant Abbott Boost Growth With Libre Duo? - Kalkine Media
How Investors Are Reacting To Abbott (ABT) Pairing Libre Duo Launch With Its Latest Dividend Approval - simplywall.st
Abbott Laboratories (ABT): One of the Best Bargain Stocks to Buy in June - Insider Monkey
Abbott Laboratories Stock (US0028241000): Quiet trading day keeps healthcare name in focus - AD HOC NEWS
Is Abbott (ABT) the Best Longevity Stock to Buy Now? - Insider Monkey
Abbott Laboratories (ABT) Announces Quarterly Dividend of $0.63 - GuruFocus
Abbott Laboratories declares $0.63 dividend - MSN
Abbott Laboratories stock underperforms Friday when compared to competitors - MarketWatch
Abbott Laboratories Keeps Quarterly Dividend at $0.63 a Share, Payable Aug. 17 to Holders of Record as of July 15 - marketscreener.com
Abbott Laboratories Declares Quarterly Cash Dividend, Payable on August 17, 2026 - marketscreener.com
Abbott recalls heart device monitoring system due to malfunction risk - Cardiovascular Business
Abbott Laboratories Stock (US0028241000): Valuation metrics in focus for S&P 500 healthcare name - AD HOC NEWS
Abbott Laboratories Stock 12‑Month Price Target Cut to $115.5, Implies 29% Upside - TradingView
BofA Securities Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $102 - 富途牛牛
BofA Adjusts Price Target on Abbott Laboratories to $102 From $120 - marketscreener.com
Abbott Laboratories seen as strong buy with 21.8–39.4% upside amid undervaluation and growth prospects. - Pluang
Abbott Laboratories (ABT) Stock Valuation Check After Recent Mixed Performance - simplywall.st
Abbott Laboratories $ABT Shares Bought by Parnassus Investments LLC - MarketBeat
IFM Investors Pty Ltd Has $45.53 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Remains Structurally Undervalued (NYSE:ABT) - Seeking Alpha
Abbott Labs is heavily oversold, says Powers Advisory Group's Matt Powers - MSN
Elfun Trusts Exits Abbott Laboratories, Impacting Portfolio by -1.97% - GuruFocus
Smithbridge Asset Management Inc. DE Raises Holdings in Abbott Laboratories $ABT - MarketBeat
Illinois Municipal Retirement Fund Has $28.27 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Dorsey & Whitney Trust CO LLC - MarketBeat
Better medical device stock right now: Abbott Laboratories vs. Dexcom - MSN
This is Why Abbott Laboratories (ABT) is One of the Best Deep Value Stock to Invest In - Yahoo Finance
Abbott Offered Faulty Health Plan Option, Ex-Worker Says - Law360
Abbott Diabetes And Cancer Milestones Contrast With Prolonged Share Price Weakness - Yahoo Finance
Abbott (ABT) Dips More Than Broader Market: What You Should Know - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):